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Embryonic stem cells (ESCs) hold promise for the
treatment of many medical conditions; however,
their utility is limited by immune rejection. The objec-
tive of our study is to establish tolerance or promote
engraftment of transplanted ESCs as well as mature
cell populations derived from ESCs. Luciferase
(luc+)-expressing ESCs were utilized to monitor the
survival of the ESCs and differentiated progeny in
living recipients. Allogeneic recipients conditioned
with fractioned total lymphoid irradiation (TLI) and
anti-thymocyte serum (ATS) or TLI plus regulatory
T cells (Treg) promoted engraftment of ESC allografts
after transplantation. Following these treatments, the
engraftment of transplanted terminally differentiated
endothelial cells derived from ESCs was also sig-
nificantly enhanced. Our findings provide clinically
translatable strategies of inducing tolerance to adop-
tively transferred ESCs for cell replacement therapy
of medical disorders.INTRODUCTION
Embryonic stem cells (ESCs) hold tremendous promise for
the treatment of a broad range of serious medical conditions,
including organ failure and neurodegenerative disorders (Murry
and Keller, 2008). However, their utility is limited by immunolog-
ical rejection upon transplantation of the allogeneic ESCs or
differentiated progeny. Rejection has been observed in animal
modeling (Pearl et al., 2012; Wu et al., 2008). One alternative is
to use autologous induced pluripotent stem cells (iPSCs) (Wu
and Hochedlinger, 2011). However, when autologous iPSCs
are not available, transplantation of allogeneic iPSCs can also
provoke an immune response. Further concerns remain about
the ability to derive differentiated functional cells and tissues
from iPSCs. Therefore, overcoming the immunogenicity or in-
ducing tolerance to ESCs and differentiated progeny remains aCellcritical issue before the promise of ESC-based treatments can
be realized.
Regulation of immune function has significant potential for
the treatment of a variety of disorders, including following
hematopoietic cell transplantation (HCT) for controlling graft-
versus-host disease (GVHD), as well as for inducing tolerance
to transplanted organs and tissues. One strategy, developed
in murine models and extended to the clinic, involves host
conditioning with fractioned total lymphoid irradiation (TLI)
and anti-thymocyte globulin (ATG). This approach has been
successfully employed to reduce the risk of GVHD after allo-
geneic HCT and to induce tolerance to transplanted solid
organ allografts (Kohrt et al., 2009; Lowsky et al., 2005; Scan-
dling et al., 2008). The mechanism underlying the protective
effects of TLI/ATG conditioning is through the altered ratio
of natural killer–T (NK-T) cells that are relatively radioresistant
as compared with conventional CD4+ and CD8+ T cells
(Tcon), resulting in a much greater NK-T/Tcon cell ratio in TLI/
ATG conditioned hosts. NK-T cells that express a common
T cell receptor recognize targets through engagement of
CD-1 and appear to require regulatory T cells for optimal ef-
fects (Hongo et al., 2012; Nador et al., 2010; Schneidawind
et al., 2014).
Another strategy to suppress alloimmune responses and
induce tolerance is through the activation or adoptive transfer
of regulatory T cells (Treg). Distinct populations of regulatory
T cells are capable of controlling immune reactions such as
CD4+CD25+Foxp3+ natural Treg (Fontenot et al., 2003; Sakagu-
chi et al., 2008). Adoptive transfer of Treg suppresses GVHD in
allogeneic animal models of HCT and in humans (Brunstein
et al., 2011; Colonna et al., 2011; Di Ianni et al., 2011; Edinger
et al., 2003; Nguyen et al., 2008).
The goal of our study was to evaluate these clinically
utilized strategies to promote the engraftment of undif-
ferentiated and differentiated ESCs. We utilized luciferase
(luc+) expressing ESCs to non-invasively track the fate of
ESCs in living animals by bioluminescent imaging (BLI)
and to explore both the engraftment of ESC populations in
allogeneic as compared with syngeneic and severe combined
immunodeficiency (SCID) hosts and assess the impact of hostReports 10, 1793–1802, March 24, 2015 ª2015 The Authors 1793
Figure 1. TLI plus ATS and TLI and ATS Alone Promoted the Engraftment of Undifferentiated ESC Allografts
(A) The schema of ESC regimen of allogeneic host conditioning with TLI/ATS. 5 3 104 undifferentiated luc+ C57BL/6 ESCs were IM injected into the allogeneic
Balb/c recipients. Ten doses of 240 cGy each were administered to the recipient animals starting on the day following ESC transplantation using 5 doses per
week. Rabbit ATS was administered by intraperitoneal injection to the recipient animals with 0.05 ml of ATS in 0.5 ml saline on days 0, 1, 2, 3, and 4 after ESC
transplantation. Both TLI and ATS were performed to TLI plus ATS group.
(legend continued on next page)
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conditioning with TLI/ATS and regulatory T cells on their
survival.
RESULTS
ESCs Were Rejected in Allogeneic Recipients after
Transplantation
We utilized BLI to noninvasively track the engraftment of ESCs
in living animals after transplantation. The C57BL/6 mESC line
(H-2Kb) was transfected with the luc gene driven by a constitu-
tive CMV promoter. There was a clear correlation between
cell number and reporter gene luc activity (Figure S1A). The
transduced luc+ ESCs had similar characteristics of self-
renewal and pluripotency to the wild-type C57BL/6 ESCs
(data not shown). To assess the survival of the luc+ mESCs
in vivo, 1 3 104, 5 3 104, 1 3 105, and 5 3 105 ESCs were in-
jected into the left gastrocnemius muscle of allogeneic Balb/c
(H-2Kd) recipients. As controls, the same number of ESCs
were injected into C57BL/6 syngeneic, Balb/c SCID, and
Balb/c mice previously transplanted with C57BL/6 TCD-BM
(BMT). The engraftment of ESCs was non-invasively assessed
by BLI every 3–5 days. In agreement with previous studies
(Pearl et al., 2011; Swijnenburg et al., 2008a; Wu et al., 2008),
the ESCs were rejected in the allogeneic recipients, with BLI
signal gradually increasing until 10–14 days after transplantation
and then decreasing, until reaching background levels at around
21 days. However, in the syngeneic, SCID and BMT groups, the
transplanted ESCs proliferated well and formed teratomas with
BLI signal continuously increasing (p < 0.0001) (Figure S1B). We
found that 5 3 104 ESCs demonstrated the most consistent
rejection and engraftment patterns after transplantation (other
cell doses data not shown), and this dose of luc+ C57BL/6
ESCs was utilized in all subsequent experiments. Non-trans-
duced C57BL/6 mESCs were studied in parallel studies, and
engraftment was assessed by the size of the teratomas by cal-
ipers where a similar rejection pattern was observed, demon-
strating that the rejection was not due to immunoreactivity
against luc (data not shown).
TLI plus ATS and TLI and ATS Alone Promoted the
Engraftment of Undifferentiated ESC Allografts
Clinically validated strategies utilized to promote the engraft-
ment of ESCs following transplantation by preparing Balb/c
hosts with TLI and ATS (Figure 1A) resulted in significant engraft-
ment of undifferentiated ESC allografts (p < 0.05) (Figure 1B). TLI
and ATS alone resulted in similar effects as the combination of
TLI and ATS in promoting engraftment of ESCs when compared
with the allogeneic group (p < 0.05 and p < 0.0001, respectively)
(Figure 1C). Representative images of individual animals are
shown in Figure 1D.(B) The quantitative BLI signal showed that the undifferentiated ESCswere routine
and C57BL/6 syngeneic control groups, the ESCs were well engrafted. Howeve
differentiated ESC allografts was demonstrated.
(C) TLI and ATS alone resulted in similar effects in promoting engraftment of ESC
(D) The representative in vivo BLI images from one experiment are shown.
n = 5 per group, *p < 0.05, ****p < 0.0001, compared with the allogeneic group, re
test. Each experiment was repeated twice, and one representative experiment is
CellTLI plus ATS and TLI and ATS Alone Promoted the
Engraftment of Differentiated ESC-EB and ESC-TC
Allografts
Aswe are concerned that undifferentiated ESCs form teratomas,
which is clearly not the ultimate goal for ESC therapy, we ex-
plored the engraftment of differentiated progeny derived from
ESCs. We used in vitro differentiated ESC-derived EB cells
(ESC-EBs) and in vivo differentiated ESC-derived teratoma cells
(ESC-TCs) to examine the impact of TLI/ATS conditioning on
engraftment of these differentiated cells (Figure 2A). After differ-
entiation, there were still an average of 65% undifferentiated
SSEA-1+ ESCs in the day 15 EBs and 10% undifferentiated
ESCs in the ESC-TCs (Figures 2A and S2A). These undifferenti-
ated SSEA-1 positive cells were depleted for subsequent studies
(Figure 2A). Compared with the low-level expression of MHC
class I (H-2Kb) in the undifferentiated ESCs, the ESC-EBs and
ESC-TCs have slightly increased expression of MHC-I, with
very little MHC-II expression detected (Figure S2A). Compared
with the allogeneic group, TLI and ATS conditioning also pro-
moted engraftment of ESC-EBs (p < 0.0001) (Figure 2B). TLI
alone and ATS alone both showed similar effects (both p <
0.05) (Figure 2C). A similar impact was also observed following
TLI plus ATS conditioning on improving the engraftment of differ-
entiated ESC-TCs (p < 0.05) (Figure 2D). However, compared
with the allogeneic group, the effect of TLI and ATS alone had
limited impact on the engraftment of the more mature ESC-
TCs, yet the combination of TLI and ATS did result in engraftment
of this cell population (Figure 2E). Forty days after transplanta-
tion, we harvested the differentiated ESC grafts from the TLI
and ATS treated groups and performed histological analysis.
The engrafted tissue still consisted of derivatives from all three
lineages, indicating that the strategy of conditioning with TLI
and ATS retains the capacity to promote engraftment of differen-
tiated cell types derived from ESCs (Figure S2B).
Regulatory T Cells Promoted the Engraftment of
Undifferentiated ESCs and Differentiated ESC-EB and
ESC-TC Allografts
Conditioning with TLI and ATG has been utilized in the clinic and
is generally well tolerated (Kohrt et al., 2009; Lowsky et al., 2005;
Scandling et al., 2008). However, ATG has significant toxicities,
which could have deleterious effects in the clinic that although
tolerated for cancer patients may be less desirable in other set-
tings. Therefore, we explored an alternative strategy utilizing
Treg. After TLI conditioning, 5 3 10
5 fluorescence-activated cell
sorting (FACS)-purified natural CD4+CD25+Foxp3+ Treg were
infused into Balb/c hosts (day 12 after the ESC transplantation;
Figure 3A). Compared with the allogeneic group, TLI plus
donor type Treg promoted the engraftment of undifferentiated
ESC allografts, which is similar to the effect in the TLI alone grouply rejected in the untreated allogeneic group, while in the untreated Balb/c SCID
r, following host conditioning with TLI plus ATS, significant engraftment of un-
s.
spectively. All values are expressed as mean ± SEM. The analysis is by ANOVA
shown. See also Figure S1.
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Figure 2. TLI plus ATS and TLI and ATS Alone Promoted the Engraftment of Differentiated ESC-EB and ESC-TC Allografts
(A) The schema of the regimen of allogeneic host conditioning with TLI/ATS. 53 104 differentiated luc+C57BL/6 ESC-EBs and ESC-TCs were IM injected into the
allogeneic Balb/c recipients. To deplete the undifferentiated ESCs from the differentiated progenies, only FACS-sorted live SSEA-1 negative cells were injected.
(B) Compared with the untreated allogeneic group, TLI and ATS conditioning promoted the engraftment of ESC-EBs.
(C) Both TLI alone and ATS alone showed similar effects as TLI plus ATS.
(D) A similar impact was also observed following TLI plus ATS conditioning on improving the engraftment of ESC-TCs.
(legend continued on next page)
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(p < 0.0001, compared with the allogeneic group) (Figure 3B).
However, with the differentiated ESC-TCs and ESC-EBs, the
infusion of donor type Treg after TLI resulted in improved engraft-
ment of these differentiated cells compared with the TLI alone
group (p < 0.01) (Figure 3C). TLI/ATG conditioning could
enhance iNK-T cells, which appeared to interact with host Treg
for optimal effects on tolerance induction to the solid organ allo-
grafts (Hongo et al., 2012; Nador et al., 2010). Since donor Treg
are generally not available, we evaluated the impact of host
Treg on the engraftment of ESC-derived cells. Similar results
were observed with the differentiated ESC-EBs, where the
impact of TLI alone treatment was very limited and was signifi-
cantly improved with the addition of host type Treg (p < 0.01)
(Figure 3D).
TLI and ATS and TLI plus Regulatory T Cells Promoted
the Engraftment of Fully Differentiated ESC-Derived
Endothelial Cell Allografts
Differentiated ESC-EBs and ESC-TCs are composed of precur-
sor cells with the capacity to differentiate into all three lineages;
however, they also have the potential for teratoma growth. Since
the goal of ESC-based therapies will likely involve the use of
differentiated cell populations, we explored the impact of these
approaches on engraftment of fully differentiated cells.We chose
fully differentiated endothelial cells (ECs) as the target cells since
protocol is available for their derivation (Huang et al., 2010) and
substantial numbers of cells could be obtained. C57BL/6 luc+
ESCs (H-2Kb) were first cultured to form EBs in suspension cul-
ture. EBs were re-plated after 3 days and further differentiated
for 3 weeks in the presence of vascular endothelial growth factor
(VEGF). At the end of the culture period, the differentiated cells
had characteristic endothelial cell morphology (Figure 4A1) and
expressed specific endothelial marker-VE-cadherin and CD31
on the SSEA-1 negative cells (Figure 4B). The differentiated
ECs also possessed endothelial cell functions in vitro, such
as forming endothelial tube-like networks when cultured on
Matrigel or gelatin (Figure 4A2), and the uptake of low-density li-
poprotein (LDL) (Figure 4A4). FACS analysis demonstrated that
15% of the cells were VE-cadherin+SSEA-1 cells from the dif-
ferentiation cultures (Figures 4B and 4D). These cells showed
much higher MHC class I (H-2Kb) expression than undifferenti-
ated ESCs, without expression of MHC class II (Figures 4C
and S2A). The VE-cadherin+SSEA-1 cells were purified to
obtain terminally differentiated ESC-derived endothelial cells
(ESC-ECs) (post-sort purity 99%), which also completely
depleted the undifferentiated SSEA-1+ ESCs (Figure 4D). After
FACS, 5 3 104 purified ESC-ECs were injected into the left gas-
trocneimus muscle of allogeneic Balb/c (H-2Kd) recipients. We
compared allogeneic host conditioning with TLI alone, TLI and
ATS, and TLI plus host Balb/c type CD4+CD25+Foxp3+ Treg
infusion to the Balb/c recipients with unprepared Balb/c recipi-
ents. The positive control groups also consisted of Balb/c SCID
and C57BL/6 syngeneic recipients without conditioning (data(E) However, compared with the allogeneic group, TLI and ATS alone had a limi
Balb/c SCID and C57BL/6 syngeneic control groups, the differentiated ESCs we
n = 5 per group, *p < 0.05, ***p < 0.0005, ****p < 0.0001, compared with the allogen
is by ANOVA test. Each experiment was repeated twice, and one representative
Cellnot shown). The cell number, transplantation, and cell survival
tracking experiments were performed as previous experiments
(Figure 4D). After transplantation, the survival of ESC-ECs was
tracked by in vivo BLI every 5 to 7 days. Unlike undifferentiated
ESC, differentiated ESC-EBs, and differentiated ESC-TCs, these
fully differentiated ESC-ECs first grow very slowly in all the recip-
ients during the first 3 weeks, with weak BLI signals (Figure 4E).
After approximately 3 weeks, the engraftment of ESC-ECs was
observed in the TLI and ATS treated group, compared with the
untreated allogeneic group (p < 0.0001). Although the ECs grew
rapidly during this period, their overall BLI intensity was much
lower than from the engrafted undifferentiated ESCs and ESC-
EBs (Figures 1B and 2B). When 5 3 105 natural host Balb/c
type Treg purified by FACS were infused to the allogeneic recipi-
ents after 10 doses of TLI at day 12 of ESC-ECs post-transplan-
tation (Figure 4D), the BLI results showed that TLI plus Treg treat-
ment can also significantly improve the engraftment of ESC-ECs
(p < 0.0005, comparedwith the allogeneic group) (Figure 4E). The
Treg infusion after TLI significantly enhanced the engraftment of
differentiated ESC-ECs when compared with animals treated
with TLI alone, where the cells engrafted minimally by 7 weeks
and then quickly rejected later at 9 weeks (p < 0.01; Figure 4E).
All of the ESC-EC allografts survived for 2 months after TLI/ATS
and TLI plus host Treg treatments. After 2 months, we harvested
the allografts and performed histological analysis. A high density
of capillary tube-like structures could be clearly observed among
themuscle fibers. Simultaneously, immunofluorescence staining
of luc and the endothelial marker CD31 demonstrated the pres-
ence of donor-derived luc and CD31 double-positive cells in
the allografts, which indicated the engraftment of transplanted
luc+ ESC-ECs (Figure 4F).
DISCUSSION
Embryonic stem cells have demonstrated ability to self-renew
and differentiate into a broad array of functional cells making
these cells attractive for clinical translation. However, rejection
of ESCs after transplantation into allogeneic recipients is a major
limitation. We confirmed that ESCs are readily rejected in agree-
ment with other studies (Pearl et al., 2011; Swijnenburg et al.,
2008a, 2008b; Wu et al., 2008). To overcome rejection, we uti-
lized clinically relevant immune regulatory strategies to promote
the engraftment of ESCs and differentiated cell populations after
allogeneic transplantation without the need for additional donor
bone marrow cells. TLI and ATS conditioning either alone or in
combination had a significant impact on promoting the engraft-
ment of ESC allografts but not differentiated progeny where
TLI and ATS together were required for similar engraftment
observed in syngeneic hosts. Treg infusion after TLI treatment
also significantly promoted the engraftment of differentiated
progeny from ESCs, especially the fully differentiated ESCs
in the allogeneic recipients. This also demonstrated that the
adoptive transfer of Treg can suppress rejection to allogeneicted effect on promoting the engraftment of the more mature ESC-TCs. In the
re well engrafted.
eic group, respectively. All values are expressed as mean ± SEM. The analysis
experiment is shown. See also Figure S2.
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Figure 3. Treg Promoted the Engraftment of Undifferentiated ESCs and Differentiated ESC-EB and ESC-TC Allografts
(A) The schema of the Treg infusion regimen. 5 3 10
4 undifferentiated luc+ C57BL/6 ESCs and FACS-sorted differentiated SSEA-1 negative ESC-EBs and ESC-
TCs were IM injected into allogeneic Balb/c recipients, the same as TLI/ATS experiments.
(B–D) After 10 doses of TLI conditioning, 5 3 105 FACS-purified C57BL/6 donor (B, C) or Balb/c host (D) type CD4+CD25+Foxp3+ Tregs were infused to Balb/c
recipients (day 12 after ESC transplantation).
(B) The quantitative BLI signal results showed that compared with the allogeneic group, TLI plus donor C57BL/6 type Tregs infusion promoted the engraftment of
undifferentiated ESC allografts, which is similar to the impact from the TLI alone group.
(C) With the differentiated ESC-TCs, the infusion of donor type Tregs after TLI resulted in improved engraftment of these differentiated cells compared with the TLI
alone group.
(D) Similar results were also observed with the differentiated ESC-EBs, where the impact of TLI alone treatment was limited and significantly improved with the
addition of host Balb/c type Treg.
n = 5 per group, **p < 0.01 comparison between TLI + Treg and TLI alone; *p < 0.05, ***p < 0.0005, ****p < 0.0001, comparedwith the allogeneic group. All values are
expressed as mean ± SEM. The analysis is by ANOVA test. Each experiment was repeated twice, and one representative experiment is shown.ESC transplanted across a major-mismatched histocompatibili-
ty complex barrier. We further explored the impact of these
clinically translatable regimens not only to the undifferentiated
ESCs, but also to the differentiated cells derived from ESCs.
The TLI/ATG regimen has been successfully used in the clinic
to induce tolerance to transplanted kidney allografts in combina-1798 Cell Reports 10, 1793–1802, March 24, 2015 ª2015 The Authortion with bone marrow transplantation from the same donor
(Scandling et al., 2008) and to suppress GVHD after allogeneic
HCT for the treatment of patients with hematological malig-
nancies (Kohrt et al., 2009; Lowsky et al., 2005; Messina et al.,
2012). In murine models, host TLI and ATS conditioning can
induce tolerance to combined solid organ and bone marrows
allografts (Hongo et al., 2012; Nador et al., 2010). Mechanistic
studies have demonstrated that this regimen promotes tolerance
by changing the balance of regulatory and conventional naive
CD4 T cells in the host, with TLI/ATS favoring NK-T cells in the
recipient that interact with CD4+CD25+ Treg in the graft (Nador
et al., 2010). Graft acceptance and donor cell engraftment
required host Treg production of IL-10 that was in turn enhanced
by the host iNK-T cell production of IL-4. Depletion of Treg before
conditioning resulted in rapid rejection of bone marrow and or-
gan allografts (Hongo et al., 2012; Nador et al., 2010).
The TLI and ATS regimens have never before been applied to
ESC transplantation. Previous studies have shown that the rejec-
tion emerging in ESC allografts is due to CD4 and CD8 T cells
that infiltrate the graft (Robertson et al., 2007; Swijnenburg
et al., 2008a; Wu et al., 2008). In our experiments, TLI/ATS
host conditioning had a significant impact on promoting the
engraftment of both undifferentiated and differentiated ESC allo-
grafts. The TLI and ATS alone treatments had similar effects on
improving the engraftment of undifferentiated ESCs as com-
bined treatment with TLI/ATS. When more differentiated ESC-
TCs and ESC-ECs were utilized, the effects of TLI or ATS alone
became more limited. In addition, when TLI/ATG conditioning
is utilized in the solid organ tolerance induction experiments
and clinical trials, it is administered in combination with bone
marrow transplantation. In our ESC transplantation experiments,
TLI plus ATS, without bone marrow transplantation, could pro-
mote the engraftment of ESC allografts, which is consistent
with previous studies (Robertson et al., 2007; Wu et al., 2008)
that ESCs have lower immunogenicity than conventional termi-
nally differentiated cells. These studies imply that there may be
a lower barrier to induce tolerance to ESCs than to solid organ
transplantation.
To evaluate the impact of these approaches on the transplan-
tation of more differentiated cell populations, which is closer to
the clinical situation, we first transplanted SSEA-1 negative
differentiated progeny from the ESC-EBs and ESC-TCs and
examined the impact of TLI/ATS and Treg on their subsequent
engraftment. We further examined these immune regulatory
strategies on the engraftment of terminally differentiated ESC-
derived endothelial cells. Importantly, conditioning with TLI/
ATS or TLI/Treg also promoted the engraftment to fully differenti-
ated ESC-derived endothelial cells. Furthermore, the induced
tolerance in both treated groups can be maintained for as long
as 2 months. Transplanted luc+ ESC-EC derived capillary tube-
like structures, which are luc+CD31+, could be observed among
the muscle fibers in the allografts, while teratoma formation was
not observed.
Naturally occurring Treg have been widely used in suppressing
GVHD and autoimmune diseases in animal models with support-
ive studies emerging in the clinic (Brunstein et al., 2011; Di Ianni
et al., 2011; Edinger et al., 2003; Nguyen et al., 2008). In the
setting of ESC transplantation, very few previous studies have
indicated that Treg play an important role in acceptance of
ESC-derived tissues transplanted across major mismatched
histocompatibility barriers (Lui et al., 2010). Co-stimulation
blockade enhanced human ESC engraftment into the testis
and heart of immunocompetent mice, and regulatory T cells
were postulated to be involved in tolerance induction (GrinnemoCellet al., 2008). In our current experiments, infusion of Treg after host
TLI conditioning resulted in enhanced engraftment of ESC allo-
grafts, both to undifferentiated and differentiated ESCs, which
confirmed the previous study implicating an important role for
Treg in ESC transplantation and also suggested that infusion
of naturally arising Treg can be a promising strategy for future
ESC-based treatments. The combination of TLI conditioning
with Treg may also reduce the toxicity of the combined TLI/ATG
regimen. Our findings highlighting the functional role of Treg com-
bined with TLI, which promotes engraftment of allogeneic trans-
planted ESCs, has some differences from our previous study
(Pearl et al., 2011). Because of the mechanistic difference of
immunosuppression strategies utilized, blocking leukocyte cos-
timulatory molecules promotes engraftment of differentiated
progeny derived from ESCs where in that setting Treg did not
play a major role (Pearl et al., 2011). We also did not observe
that Treg alone promoted engraftment of any ESC-derived tissue.
In our current studies, the adoptive transfer of Treg after host TLI
conditioning made a significant contribution to promote engraft-
ment of differentiated ESC progeny, which is in agreement with
previous iNK-T/Treg mechanistic findings from TLI/ATS tolerance
induction animal experiments (Hongo et al., 2012; Nador et al.,
2010). These conditions are quite different and highlight the
importance of the specific approach to promote engraftment
of these differentiated cells and tissues when clinical translation
is contemplated.
In conclusion, our findings demonstrate that TLI plus ATS and
TLI plus Treg infusion can promote the engraftment of ESC and
differentiated progeny allografts, which not only provides in-
sights into the mechanisms of the immune rejection of ESCs
but also develops clinically translatable strategies of inducing
tolerance to adoptively transferred ESCs for the future treatment
of medical disorders.EXPERIMENTAL PROCEDURES
Culturing, Transduction, Transplantation, and Host Conditioning
with TLI, ATS, Treg Infusion, and In Vivo BLI Tracking of ESCs
The C57BL/6 mESC cell line derived from wild-type C57BL/6 (H-2Kb) mice
purchased from ATCC (Manassas, VA) was cultured and transduced with a
reporter gene construct carrying the firefly luc driven by a constitutive
CMV promoter using techniques as previously described (Pearl et al.,
2011; Swijnenburg et al., 2008a, 2008b). 5 3 104 luc+ undifferentiated
C57BL/6 mESCs, FACS-sorted SSEA-1 negative in vitro differentiated
ESC-EBs, in vivo differentiated ESC-TCs, and in vitro differentiated ESC-
ECs (Huang et al., 2010) were injected intramuscularly (IM) into the left
gastrocnemius muscle of allogeneic Balb/c (H-2Kd) mice recipient and
controls including C57BL/6 syngeneic, Balb/c SCID, and lethally irradiated
Balb/c mice previously transplanted with T cell depleted bone marrow
(TCD-BM) cells from C57BL/6 mice (BMT). Allogeneic Balb/c host condition-
ing with 10 doses of 240 cGy TLI and 5 doses of ATS was performed as pre-
viously described (Hongo et al., 2012; Nador et al., 2010). 5 3 105 donor
C57BL/6 or host Balb/c type Treg were injected intravenously into Balb/c re-
cipients after TLI and at 12 days after ESCs transplantation. Isolation and pu-
rification of Treg was performed as previously described (Edinger et al., 2003;
Nguyen et al., 2008). Each group consisted of at least five mice and each
experiment was repeated at least two times. Animal protocols were
approved by the Institutional Animal Care and Use Committee of Stanford
University. The engraftment of ESCs was non-invasively assessed by serial
BLI every 3–5 days. BLI was performed as described previously (Swijnenburg
et al., 2008a) with an IVIS 200 or IVIS spectrum charge-coupled deviceReports 10, 1793–1802, March 24, 2015 ª2015 The Authors 1799
Figure 4. TLI and ATS and TLI plus Treg Promoted the Engraftment of Fully Differentiated ESC-Derived Endothelial Cell Allografts
(A) In vitro characterization of cultured luc+ C57BL/6 ESC-derived endothelial cells (ESC-ECs) demonstrating endothelial morphology after the 3-week VEGF
induced differentiation (A1), and typical EC functions in vitro, such as forming endothelial tube-like networks (A2), uptake of low-density lipoprotein (LDL), where
the Rodamine labeled Dil-ac-LDL can be observed in the ECs under the fluorescence microscope (A4), when compared with the phase contrast image of all the
cells on the left (A3).
(B) ESC-ECs expressed the specific endothelial marker-VE-cadherin and CD31.
(C) ESC-ECs expressed increased MHC I (H-2Kb) and did not express MHC II.
(legend continued on next page)
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imaging system (Xenogen). Images were analyzed with Living Image Soft-
ware 4.1 (Caliper Life Sciences). Differences in BLI signals among different
groups were analyzed with the ANOVA test using GraphPad Prism v6.0 soft-
ware, and p < 0.05 was considered statistically significant. More detailed
methodological information is available in the Supplemental Experimental
Procedures.
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